Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CH0012005267
Ticker NVS
Company NOVARTIS
Currency $
Price
Aware Investor Index (AII) 2.4427
Recommendation BUY
P/E 21.76
ROE 13.04 %
Capitalization 210,615,930,000 $
Dividend Yield 3.23 %
P/S 4.29
AII Position 187
P/E Position 302
ROE Position 266
Capitalization Position 38
Dividend Yield Position 210
Sales 49,109,000,000 $
10-Year Average Earnings 9,680,800,000 $
Shares Outstanding 2,371,000,000
Equity 74,227,000,000 $
Dividend per Share 2.87 $
Industry Pharmaceutical
Country Switzerland
NOVARTIS Investor Relations Web Site http://www.novartis.com/investors/index.shtml







Sales:

YEAR MONTH AMOUNT
2017 12 49,109,000,000.00 $
2016 12 48,518,000,000.00 $
2015 12 49,414,000,000.00 $
2014 12 52,180,000,000.00 $
2013 12 51,869,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 7,703,000,000.00 $
2016 12 6,698,000,000.00 $
2015 12 17,794,000,000.00 $
2014 12 10,280,000,000.00 $
2013 12 9,292,000,000.00 $
2012 12 9,383,000,000.00 $
2011 12 9,072,000,000.00 $
2010 12 9,969,000,000.00 $
2009 12 8,454,000,000.00 $
2008 12 8,163,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 74,227,000,000.00 $
2016 12 74,891,000,000.00 $
2015 12 77,122,000,000.00 $
2014 12 70,884,000,000.00 $
2013 12 74,472,000,000.00 $
2012 12 69,219,000,000.00 $
2011 12 65,940,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 2,371,000,000
2016 12 2,400,000,000
2015 12 2,438,000,000
2014 12 2,470,000,000
2013 12 2,479,000,000
2012 12 2,418,145,330
2011 12 2,406,700,000

 












Bloomberg News for NOVARTIS:



Google News for NOVARTIS:

The RNS Daily - 1 day ago
Novartis AG (NVS): Lots of Hype?
Novartis AG (NYSE:NVS) stock enjoyed an overall uptrend of 3.74% from the beginning of 2019. The closing share price quoted for February ...
Fairfield Current
Raymond James Trust Upped Its Holding in Novartis Ag Sponsored ...
Raymond James Trust Upped Its Holding in Novartis Ag Sponsored Adr (NVS) by $1.20 Million as Shares Rose; Lionstone Capital ...
The Yomi Blog (blog)
Novartis (NVS) receives FDA approval for Egaten for the treatment of ...
Novartis (NYSE: NVS) announced today that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the ...
Weston Business Review
Taking Aim at Novartis Ag (NVS) Shares
Novartis Ag (NVS)'s Aroon Up level has reached above the key level of 70, indicating a strong upward trend for the security. The Aroon ...
The Hi New Ulm - 9 minutes ago
The Technical Case For Continuing To Love Novartis AG (NVS)
A handful of technical analysis tools are suggesting that Novartis AG (NYSE:NVS) overall gets 80% Buy rating. The stock is also flashing a Buy ...
StreetInsider.com - 2 days ago
A Point Investors Can't Afford To Forget: Novartis AG (NVS), Mercury ...
NVS trading volume has lost -15729 shares compared to readings over the past three months as it recently exchanged 2424271 shares.
Zeeland Press - 14 hours ago
Bourgeon Capital Management Raised Its Holding in Novartis Ag F ...
Bourgeon Capital Management Raised Its Holding in Novartis Ag F Sponsored Adr 1 (NVS) as Shares Rose; As Lyondellbasell Indu (LYB) ...
KYMA News - 2 days ago
Novartis: Potential Fourth Quarter Earnings Trade
We have been long Novartis (NVS) for many months now and our cost basis is just above the $74 level. The firm announces its fourth quarter ...
The RNS Daily
50811 Shares in Novartis AG (NVS) Purchased by Duff & Phelps ...
Duff & Phelps Investment Management Co. acquired a new position in Novartis AG (NYSE:NVS) during the 4th quarter, according to the ...
Fairfield Current
Signal Inspection for This Stock: Novartis AG (NYSE:NVS): AO Level ...
Following trading action on shares of Novartis AG (NYSE:NVS), we see that the stock has moved 0.34 since the opening price of 89.54. So far ...


Back